ABBV trades around $285, marginally below the average analyst target of $292.21, with the 50‑day MA holding support and volume‑weighted RSI trending above 55, indicating continued upside potential. Upcoming ESMO data and strong dividend growth reinforce a bullish outlook.

Market sentiment remains upbeat as investors focus on AbbVie’s expanding oncology pipeline and its reputation as a dividend stalwart. The recent correction headline appears limited to short‑term profit‑taking rather than fundamentals.

Long‑term risk is low given diversified revenue streams and a pipeline that mitigates patent cliff exposure, though regulatory setbacks on any solid‑tumor trial could add volatility. The dividend yield above 4% offers a cushion for income‑focused holders.

Technical indicators show a bullish flag pattern forming on the daily chart, with MACD crossing above signal and increasing on‑balance volume over the past week. Data‑driven models flag a 12‑month price target above $300, aligning with analyst expectations.